Topic: infectious disease
Here is some other vaccine news of note for the week.
A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.
The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.
Amid a devastating outbreak in Nigeria, Themis plans to be first to test a Lassa fever vaccine in humans as early as this year.
BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.
Moderna has several vaccines in phase 1 development, including against CMV, HMPV/PIV3, influenza, Zika and chikungunya.
The public-private vaccine coalition will support Themis' development of Lassa fever and MERS vaccines through phase 2.
“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” said Sanofi.
The Philippine DOH is now officially asking Sanofi to refund some $39 million for used Dengvaxia doses as well.